Table IV.
Comparison of results between the ALSYMPCA trial, other retrospective studies on Radium-223 and the present study.
| Author | Type of study | No. pts. | Concomitant abiraterone/enzalutamide | 6 cycles | ORR | DCR | ALP response | PSA response | NRS response | PFS months | OS months | tSRE months | SRE | Toxicities grade 3–4 | (Refs.) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALSYMPCA trial | Phase III placebo-controlled | 614 | No | 63% | – | – | 47% | 16% | 30% | – | 14.9 | 15.6 | 33% | 56% | (6–9) |
| Dan et al | Retrospective | 11 | No | – | – | – | – | <22% | – | – | – | – | – | 18% | (11) |
| Modi et al | Retrospective | 29 | Yes | 38% | 14% | 38% | <55% | 10% | – | – | – | – | – | – | (13) |
| Etchebehere et al | Retrospective | 110 | Yes | 53% | – | – | – | – | – | 4.3 | 11.7 | 8.6 | 22% | – | (18) |
| Jadvar et al | Retrospective | 25 | No | 24% | – | – | 44% | 20% | – | – | – | – | – | – | (19) |
| McKay et al | Retrospective | 135 | Yes | 62% | – | – | – | 27% | – | – | 7.3 | 3 | 27% | 28% | (20) |
| Alva et al | Retrospective | 145 | No | 51% | – | – | 48% | 16% | 51% | – | – | – | – | 13% | (21) |
| Küronya et al | Retrospective | 41 | No | 78% | – | – | 22% | 0% | 81% | – | – | – | – | 15% | (22) |
| Wong et al | Retrospective | 64 | Yes | 55% | – | – | 55% | 12% | – | – | 12.9 | 4.4 | – | – | (29) |
| De Luca et al | Retrospective | 48 | No | 44% | – | – | 52% | – | 47% | – | – | – | – | – | (30) |
| Our study | Retrospective | 32 | No | 91% | 41% | 91% | 56% | 25% | 50% | 12 | 14 | 9.5 | 9% | 16% |
No. pts, number of patients; ORR, overall response rate; DCR, disease control rate; ALP, alkaline phosphatase; PSA, prostate-specific antigen; NRS, numerical rate scale; PFS, progression-free survival; OS, overall survival; tSRE, time to skeletal-related events; SRE, skeletal-related events.